2009-011675-79: A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS®) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC®) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR MOLECULAR RESPONSE (MMR). |
|
|
| Ongoing | 2 | 50 | Europe | PIOGLITAZONE HYDROCHLORIDE, ACTOS 15 mg, ACTOS 15 mg | CH-Versailles | chronic phase chronic myelogenous leukaemia (CP-CML) patients in major molecular response. | | | | |
EDI-PIO, NCT02852486: Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response |
|
|
| Active, not recruiting | 2 | 31 | RoW | Pioglitazone 30 Mg Oral Tablet, cloridrato de pioglitazona 30mg EMS S/A, Brasil, imatinib discontinuation | University of Campinas, Brazil | Leukemia, Chronic Myeloid | 02/24 | 02/24 | | |
ACTIW, NCT02767063: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR |
|
|
| Recruiting | 1/2 | 100 | Europe | Pioglitazone, Avelumab | Versailles Hospital | Leukemia, Myeloid, Chronic-Phase | 11/22 | 06/23 | | |
